Daniel M. Jorgensen

Daniel Jorgensen, MD, MPH, MBA, is an accomplished leader in the healthcare and pharmaceutical industries, currently serving as Chief Executive Officer of the Critical Path Institute since October 2022. Previous roles include Chief Executive Officer at AxoProtego Therapeutics and Chief Medical Officer positions at Ocugen, Crestovo, and Cellceutix Corporation. Daniel has extensive experience in clinical development and research, having held significant roles at PolyMedix, AMAG Pharmaceuticals, and Pfizer, where responsibilities included senior leadership in global research and development. Daniel's educational background includes advanced degrees in medicine and public health from esteemed institutions such as Emory University and the University of Washington, complemented by an MBA from Yale University.